Share-based Payment Arrangement, Expense of HALOZYME THERAPEUTICS, INC. from 31 Dec 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
HALOZYME THERAPEUTICS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2010 to 31 Dec 2025.
  • HALOZYME THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $16,571,000, a 45% increase year-over-year.
  • HALOZYME THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $51,565,000, a 19% increase year-over-year.
  • HALOZYME THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2025 was $51,565,000, a 19% increase from 2024.
  • HALOZYME THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $43,385,000, a 18% increase from 2023.
  • HALOZYME THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $36,620,000, a 50% increase from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

HALOZYME THERAPEUTICS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $51,565,000 $16,571,000 +$5,109,000 +45% 01 Oct 2025 31 Dec 2025 10-K 17 Feb 2026 2025 FY
Q3 2025 $46,456,000 $12,160,000 -$418,000 -3.3% 01 Jul 2025 30 Sep 2025 10-Q 03 Nov 2025 2025 Q3
Q2 2025 $46,874,000 $12,161,000 +$2,690,000 +28% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $44,184,000 $10,673,000 +$799,000 +8.1% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $43,385,000 $11,462,000 +$1,797,000 +19% 01 Oct 2024 31 Dec 2024 10-K 17 Feb 2026 2025 FY
Q3 2024 $41,588,000 $12,578,000 +$3,211,000 +34% 01 Jul 2024 30 Sep 2024 10-Q 03 Nov 2025 2025 Q3
Q2 2024 $38,377,000 $9,471,000 -$151,000 -1.6% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $38,528,000 $9,874,000 +$1,908,000 +24% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $36,620,000 $9,665,000 +$2,442,000 +34% 01 Oct 2023 31 Dec 2023 10-K 17 Feb 2026 2025 FY
Q3 2023 $34,178,000 $9,367,000 +$2,570,000 +38% 01 Jul 2023 30 Sep 2023 10-Q 31 Oct 2024 2024 Q3
Q2 2023 $31,608,000 $9,622,000 +$3,987,000 +71% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $27,621,000 $7,966,000 +$3,224,000 +68% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $24,397,000 $7,223,000 +$2,097,000 +41% 01 Oct 2022 31 Dec 2022 10-K 18 Feb 2025 2024 FY
Q3 2022 $22,300,000 $6,797,000 +$1,398,000 +26% 01 Jul 2022 30 Sep 2022 10-Q 06 Nov 2023 2023 Q3
Q2 2022 $20,902,000 $5,635,000 +$263,000 +4.9% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $20,639,000 $4,742,000 -$181,000 -3.7% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $20,820,000 $5,126,000 +$930,000 +22% 01 Oct 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
Q3 2021 $19,890,000 $5,399,000 +$1,179,000 +28% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $18,711,000 $5,372,000 +$1,115,000 +26% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $17,596,000 $4,923,000 +$392,000 +8.7% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $17,204,000 $4,196,000 -$3,033,000 -42% 01 Oct 2020 31 Dec 2020 10-K 21 Feb 2023 2022 FY
Q3 2020 $20,237,000 $4,220,000 -$4,019,000 -49% 01 Jul 2020 30 Sep 2020 10-Q 02 Nov 2021 2021 Q3
Q2 2020 $24,256,000 $4,257,000 -$5,576,000 -57% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 $29,832,000 $4,531,000 -$4,944,000 -52% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q4 2019 $34,776,000 $7,229,000 -$1,783,000 -20% 01 Oct 2019 31 Dec 2019 10-K 22 Feb 2022 2021 FY
Q3 2019 $36,559,000 $8,239,000 -$628,000 -7.1% 01 Jul 2019 30 Sep 2019 10-Q 02 Nov 2020 2020 Q3
Q2 2019 $37,187,000 $9,833,000 +$355,000 +3.7% 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 $36,832,000 $9,475,000 +$1,136,000 +14% 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $35,696,000 $9,012,000 +$1,610,000 +22% 01 Oct 2018 31 Dec 2018 10-K 23 Feb 2021 2020 FY
Q3 2018 $34,086,000 $8,867,000 +$1,105,000 +14% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $32,981,000 $9,478,000 +$1,287,000 +16% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $31,694,000 $8,339,000 +$1,024,000 +14% 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $30,670,000 $7,402,000 +$660,000 +9.8% 01 Oct 2017 31 Dec 2017 10-K 24 Feb 2020 2019 FY
Q3 2017 $30,010,000 $7,762,000 +$1,107,000 +17% 01 Jul 2017 30 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $28,903,000 $8,191,000 +$1,820,000 +29% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $27,083,000 $7,315,000 +$1,498,000 +26% 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q4 2016 $25,585,000 $6,742,000 +$1,492,000 +28% 01 Oct 2016 31 Dec 2016 10-K 21 Feb 2019 2018 FY
Q3 2016 $24,093,000 $6,655,000 +$1,102,000 +20% 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $22,991,000 $6,371,000 +$466,000 +7.9% 01 Apr 2016 30 Jun 2016 10-Q 08 Aug 2017 2017 Q2
Q1 2016 $22,525,000 $5,817,000 +$1,687,000 +41% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q4 2015 $20,838,000 $5,250,000 +$1,041,000 +25% 01 Oct 2015 31 Dec 2015 10-K 20 Feb 2018 2017 FY
Q3 2015 $19,797,000 $5,553,000 +$1,377,000 +33% 01 Jul 2015 30 Sep 2015 10-Q 07 Nov 2016 2016 Q3
Q2 2015 $18,420,000 $5,905,000 +$2,311,000 +64% 01 Apr 2015 30 Jun 2015 10-Q 09 Aug 2016 2016 Q2
Q1 2015 $16,109,000 $4,130,000 +$835,000 +25% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016 2016 Q1
Q4 2014 $15,274,000 $4,209,000 +$1,811,000 +76% 01 Oct 2014 31 Dec 2014 10-K 28 Feb 2017 2016 FY
Q3 2014 $13,463,000 $4,176,000 +$1,872,000 +81% 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015 2015 Q3
Q2 2014 $11,591,000 $3,594,000 +$1,155,000 +47% 01 Apr 2014 30 Jun 2014 10-Q 10 Aug 2015 2015 Q2
Q1 2014 $10,436,000 $3,295,000 +$898,000 +37% 01 Jan 2014 31 Mar 2014 10-Q 11 May 2015 2015 Q1
Q4 2013 $9,538,000 $2,398,000 +$411,373 +21% 01 Oct 2013 31 Dec 2013 10-K 29 Feb 2016 2015 FY
Q3 2013 $9,126,627 $2,304,000 +$381,607 +20% 01 Jul 2013 30 Sep 2013 10-Q 10 Nov 2014 2014 Q3
Q2 2013 $8,745,020 $2,439,000 +$153,948 +6.7% 01 Apr 2013 30 Jun 2013 10-Q 11 Aug 2014 2014 Q2
Q1 2013 $8,591,072 $2,397,000 +$242,072 +11% 01 Jan 2013 31 Mar 2013 10-Q 12 May 2014 2014 Q1
Q4 2012 $8,349,000 $1,986,627 01 Oct 2012 31 Dec 2012 10-K 02 Mar 2015 2014 FY
Q3 2012 $1,922,393 +$165,034 +9.4% 01 Jul 2012 30 Sep 2012 10-Q 08 Nov 2013 2013 Q3
Q2 2012 $2,285,052 +$1,057,154 +86% 01 Apr 2012 30 Jun 2012 10-Q 07 Aug 2013 2013 Q2
Q1 2012 $2,154,928 01 Jan 2012 31 Mar 2012 10-Q 08 May 2013 2013 Q1
Q3 2011 $1,757,359 01 Jul 2011 30 Sep 2011 10-Q 08 Nov 2012 2012 Q3
Q2 2011 $1,227,898 01 Apr 2011 30 Jun 2011 10-Q 09 Aug 2012 2012 Q2

HALOZYME THERAPEUTICS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $51,565,000 +$8,180,000 +19% 01 Jan 2025 31 Dec 2025 10-K 17 Feb 2026 2025 FY
2024 $43,385,000 +$6,765,000 +18% 01 Jan 2024 31 Dec 2024 10-K 17 Feb 2026 2025 FY
2023 $36,620,000 +$12,223,000 +50% 01 Jan 2023 31 Dec 2023 10-K 17 Feb 2026 2025 FY
2022 $24,397,000 +$3,577,000 +17% 01 Jan 2022 31 Dec 2022 10-K 18 Feb 2025 2024 FY
2021 $20,820,000 +$3,616,000 +21% 01 Jan 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
2020 $17,204,000 -$17,572,000 -51% 01 Jan 2020 31 Dec 2020 10-K 21 Feb 2023 2022 FY
2019 $34,776,000 -$920,000 -2.6% 01 Jan 2019 31 Dec 2019 10-K 22 Feb 2022 2021 FY
2018 $35,696,000 +$5,026,000 +16% 01 Jan 2018 31 Dec 2018 10-K 23 Feb 2021 2020 FY
2017 $30,670,000 +$5,085,000 +20% 01 Jan 2017 31 Dec 2017 10-K 24 Feb 2020 2019 FY
2016 $25,585,000 +$4,747,000 +23% 01 Jan 2016 31 Dec 2016 10-K 21 Feb 2019 2018 FY
2015 $20,838,000 +$5,564,000 +36% 01 Jan 2015 31 Dec 2015 10-K 20 Feb 2018 2017 FY
2014 $15,274,000 +$5,736,000 +60% 01 Jan 2014 31 Dec 2014 10-K 28 Feb 2017 2016 FY
2013 $9,538,000 +$1,189,000 +14% 01 Jan 2013 31 Dec 2013 10-K 29 Feb 2016 2015 FY
2012 $8,349,000 +$2,779,101 +50% 01 Jan 2012 31 Dec 2012 10-K 02 Mar 2015 2014 FY
2011 $5,569,899 +$703,574 +14% 01 Jan 2011 31 Dec 2011 10-K 28 Feb 2014 2013 FY
2010 $4,866,325 01 Jan 2010 31 Dec 2010 10-K 01 Mar 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.